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ABSTRACT
Invasive fungal infections have extremely high rates of morbidity and mortality, particularly in
immunocompromised hosts. Combination antifungal therapy is conceptually attractive as a life-saving
measure. However, in-vitro and in-vivo evidence is often conflicting and clinical trials in this area are
limited. Most clinical studies show similar outcomes for combination antifungal therapy when
compared to monotherapy, although secondary endpoints and sub-analyses often show advantages for
the combinations in endpoints such as culture sterilisation. The logistics of large clinical trials of
combination therapy are highly complex. Combination of antifungals with immune modulators is an
exciting new research area. Until more data are available, clinicians should approach combination
antifungal therapy with caution.
Keywords Antifungals, azoles, combination therapy, echinocandins, fungal infection, immune modu-
lators, polyenes, review
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INTRODUCTION
Invasive fungal infections have extremely high
rates of morbidity and mortality, particularly in
immunocompromised hosts [1]. Clinicians caring
for these populations are often frustrated by long,
complicated, and expensive courses of therapy
that usually result in a constant stream of lost
patients who succumb to these infections despite
having ‘survived’ their underlying diseases and
other disease-modifying therapies.
Drawing from experiences in other areas of
antimicrobial chemotherapy, combination anti-
fungal therapy (CbAT) is conceptually attractive
as a life-saving measure, since it offers the
possibility of synergy or at least additivity, and
perhaps even reduced dosing with substantial
savings in terms of money and toxicity.
CbAT has been extensively studied in vitro and
in animal models. Classic in-vitro experiments
and animal models indicate that almost any result
can be achieved for any combination, depending
on the testing conditions and strains used [2].
However, certain patterns have emerged in these
models; they include antagonism between azoles
and polyenes, which is not, interestingly, mani-
fested in patient trials where azoles and polyenes
have been given sequentially; and for the most
part, synergy between echinocandins and other
agents [2]. A summary of common in-vitro and
in-vivo patterns of antifungal drug interactions is
shown in Table 1.
Clinical evidence for or against CbAT is lim-
ited. It is composed for the most part of anecdotal
reports or retrospective case series, and a few
randomised controlled trials. Table 2 lists the
major randomised clinical trials involving CbAT.
This article will review currently available
clinical evidence for CbAT for selected fungal
infections, identifying areas for future research.
CRYPTOCOCCOSIS
The first classic study investigating the combina-
tion of amphotericin B and flucytosine for men-
ingeal cryptococcosis was published in 1979.
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Bennett et al. [3] compared amphotericin B given
for 10 weeks with amphotericin B plus flucyto-
sine given for 6 weeks in 50 patients. The study
showed similar success and relapse rates, and
furthermore, that the combination was associated
with statistically significantly faster cerebrospinal
fluid (CSF) sterilisation and less nephrotoxicity.
In a follow-up study in human immunodefi-
ciency virus (HIV)-positive patients published in
1997, Van de Horst et al. [4] compared treatment
with amphotericin B alone with amphotericin B
plus flucytosine for 2 weeks, followed by 8 weeks
of oral fluconazole or itraconazole, in 381 patients.
Although the study showed that there were no
statistically significant differences between the
two groups, in secondary analyses, patients who
received the combination were more likely to give
negative CSF cultures.
In a more recent study, Brouwer et al. [5]
compared amphotericin B alone with amphoteri-
cin B plus flucytosine, amphotericin B plus fluco-
nazole, or triple therapy in 64 HIV-positive
patients. Although limited by the size of each of
the arms, the study showed that the combination
of amphotericin B plus flucytosine was superior
to amphotericin B alone or all other combinations
in the time to clear the CSF using the novel
technique of quantitative CSF cultures.
As shown above, although none of these
studies has shown a difference in clinical out-
comes when a combination is used, all point to
faster CSF sterilisation. These studies have
resulted in the combination of amphotericin B
plus flucytosine being recognised as the preferred
initial regimen for the treatment of this infection
[6].
INVASIVE CANDIDIASIS
Although evidence for the combination of ampho-
tericin B plus flucytosine for the treatment of
invasive candidiasis is mostly anecdotal, studies
have shown the combination to be more effective
than fluconazole in various disease states, such as
peritonitis, meningitis, and osteomyelitis [7–9].
This has resulted in a recommendation to use
these agents for the treatment of severe or deep
forms of invasive disease [10,11].
The largest CbAT clinical trial for patients
with invasive candidiasis was published in 2003.
Rex et al. [12] treated 219 patients with inva-
sive candidiasis with fluconazole 800 mg ⁄day
Table 1. Common in-vitro and in-vivo antifungal interaction patternsa
Fungal species ⁄drug combinations Common in-vitro patterns Common in-vivo patterns
Cryptococus neoformans
Amphotericin B + flucytosine Indifference, antagonism,
synergy
Improved or worse survival and
reduced tissue burden
Azoles + flucytosine Indifference, synergy Improved or worse survival and
reduced tissue burden
Amphotericin B and azoles Indifference Improved or worse survival and
reduced tissue burden
Echinocandins + amphotericin B Synergy NA
Echinocandins + azoles Indifference NA
Candida spp.
Amphotericin B + flucytosine Synergy, indifference Improved survival or reduced tissue burden
Azoles + flucytosine Synergy, indifference,
antagonism
Improved survival or reduced tissue burden
Amphotericin B and azoles Antagonism Improved, similar or worse survival and
reduced or unchanged tissue burden
Echinocandins + amphotericin B Indifference Improved or unchanged tissue burden
Aspergillus spp.
Amphotericin B + flucytosine Synergy, indifference,
antagonism
Improved survival
Amphotericin B and azoles Synergy, indifference,
antagonism
Unchanged or worse survival
Echinocandins + amphotericin B Synergy, indifference Improved survival, reduced or unchanged
tissue burden
Echinocandins + azoles Synergy, indifference Improved survival, unchanged tissue burden
aAbstracted from [2]. NA, not available.
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or fluconazole 800 mg ⁄day + amphotericin B
0.7 mg ⁄ kg ⁄day. Although there was an
APACHE II score imbalance between the two
groups, the study showed that the primary
clinical outcomes were similar for both groups.
Secondary analyses showed that patients in the
group that received the combination had a statis-
tically significantly shorter duration of funga-
emia. Although there was no treatment arm with
amphotericin B alone, this trial failed to show
antagonism (clinical or in vitro) for the combina-
tion of azoles and polyenes, which up to that
point had been an important concern brought
forward by theoretical interference between the
described mechanisms of action of both drug
classes and in-vitro data [2].
INVASIVE ASPERGILLOSIS
Mortality andmorbidity rates inpatientswith inva-
sive aspergillosis and infections by other filamen-
tous fungi, such as the Zygomycetes, remain high
despite significant advances in therapy and diag-
nosis [13–16]. It is in this setting that CbAT seems to
be more attractive and clinicians are more willing
to try it without much evidence to support it.
Most of the clinical evidence in this area comes
from relatively small retrospective case series or
prospective open-label studies. The four most
significant studies will be discussed in this sec-
tion.
Kontoyiannis et al. [17] retrospectively
reviewed 23 patients with proven or probable
and 25 patients with possible invasive aspergillo-
sis who were treated with concomitant caspofun-
gin plus liposomal amphotericin B in 2001 in a
reference oncology centre. The majority of the
patients received the combination as a result of
progression of disease while on liposomal
amphotericin B alone. The overall response rate
observed was 42%, which is similar to what has
been observed for other antifungal agents in both
the primary therapy and salvage settings. Factors
associated with increased likelihood of failure
were: documented disease, previous corticoste-
roid therapy, and transfer to the intensive care
unit. Only 15% of patients developed mild-to-
moderate renal insufficiency.
In a follow-up study of the same centre,
Kontoyiannis et al. [18] also described their
10-year retrospective experience in 101 haemato-
logical malignancy patients who received eitherT
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liposomal amphotericin B alone or, in 11 cases,
liposomal amphotericin B plus itraconazole (oral
solution or intravenous formulation) for the
treatment of invasive aspergillosis. The study
was limited by the wide time span of the
study and the number of evaluable patients in
the combination arm. Nevertheless, the authors
reported unusually low response rates of 10%
for the patients who received liposomal ampho-
tericin B and 0% for those who received the
combination, concluding that the addition of
itraconazole to the polyene did not provide any
benefit. Similar findings were described for this
combination in another size-limited study by
Popp et al. [19].
Marr et al. [20] restrospectively reviewed 47
patients who failed therapy with polyenes for
invasive aspergillosis and were treated with
voriconazole alone (31 patients) or voriconazole
plus caspofungin (16 patients) from 1991 to 2001
in a reference oncology centre. This small explor-
atory study showed that in the salvage setting,
survival was significantly prolonged for patients
who received the combination when compared to
the patients who received voriconazole mono-
therapy (p 0.048). Nevertheless, the authors were
cautious in their conclusions, due to the small size
and non-contemporary selection of cases and
controls.
Singh et al. [14] prospectively reviewed 40
solid-organ transplant patients from multiple
centres who were treated with caspofungin plus
voriconazole for invasive aspergillosis from 2003
to 2005, comparing them to 47 control patients
who were treated with liposomal amphotericin B
from 1999 to 2002. Survival at 90 days was 67.5%
for the patients who received the combination vs.
51% for those who received the monotherapy
(p 0.11). On secondary analysis, the authors
found that the patients who benefited from the
combination were those with renal failure or with
infection by Aspergillus fumigatus. As in other
studies, the authors also failed to find any
correlation between clinical outcomes and in-vitro
synergy testing.
More recently, Caillot et al. [21] conducted a
randomised, multicentre, open-label, pilot study
comparing high-dose liposomal amphotericin B
(10 mg ⁄kg ⁄day) with reduced-dose liposomal
amphotericin B (3 mg ⁄ kg ⁄day) plus caspofungin
in 30 patients with haematological malignancies
and invasive aspergillosis (COMBISTRAT trial).
Response rates at the end of treatment were 67%
for patients receiving the combination vs. 27% for
those who received monotherapy (p 0.028). Sur-
vival rates at 12 weeks were similar, at 100% for
the patients who received the combination and
80% for those who received the monotherapy.
Doubling of serum creatinine was observed in
23% of the patients who received monotherapy
vs. 7% of those who received the lower-dose
combination. The authors concluded that a larger
clinical trial is feasible and warranted.
IMMUNE MODULATORS AND
FUTURE RESEARCH
As seen from the clinical evidence above, a large,
randomised, controlled clinical trial is lacking.
Such a clinical trial is particularly important for
invasive aspergillosis, where the morbidity and
mortality remain high. The logistics of such a trial
have been discussed extensively in the literature
[20,22]. Major obstacles include: the number of
patients needed to adequately power the study,
the relatively low number of cases occurring
every year throughout the world, the relative
concentration of cases in centres that handle
highly immunocompromised patients, with other
cases occurring sporadically in other centres,
competing clinical trials, the lack of acceptance
of early diagnostic markers, as surrogates for both
diagnosis and outcome (to facilitate enrolment
and adjudication of cases), the lack of consensus
about which drug combinations should be stud-
ied, and the lack of consensus regarding the
comparators ⁄number of study arms. At this time,
the most interesting combination seems to be that
of an echinocandin and voriconazole, although
many researchers still express interest in a com-
bination trial with a polyene plus an echinocandin
or an azole. A major pharmaceutical company is
currently planning a multicentre, randomised,
controlled trial with an anidulafungin plus voric-
onazole vs. voriconazole alone for primary ther-
apy of patients with invasive aspergillosis
(Clinicaltrials.gov identifier NCT00531479).
Another very interesting concept for CbAT is
that of combination of an antifungal with an
immune modulator, instead of the combination of
two antifungal agents. While experience with
immune modulators is limited to date, there are
at least two studies that have explored their use in
a systematic fashion for fungal pathogens.
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In a small, randomised, placebo-controlled trial,
Pappas et al. [23] explored amphotericin B ± flu-
cytosine with recombinant interferon-c1b for HIV
patients with cryptococcal meningitis. The study
showed similar combined clinical andmycological
outcomes, but as with other combination studies,
among 75 patients, CSF clearance rates at 2 weeks
were 13% for the traditional treatment and
36% ⁄ 32% for the two recombinant interferon-c1b
dosing arms. Therapy with recombinant inter-
feron-c1b was well-tolerated in this study.
In the area of invasive candidiasis, Pachl et al.
[24] conducted a randomised, placebo-controlled
trial of lipid amphotericin B plus a recombinant
human monoclonal antibody against heat-shock
protein 90. Of 119 patients in the modified intent-
to-treat study population, a complete response
rate was observed for 48% of patients treated
with the lipid amphotericin B formulation vs.
84% of those patients who received the com-
bination (p <0.001). Similar responses were
observed in sub-analayses evaluating clinical
response, mycological response, and investiga-
tor-attributed mortality. The reason for the low
response rate seen for the patients who received
lipid amphotericin B preparations is unknown.
The monoclonal antibody was well-tolerated.
Experience with immune modulators in asper-
gillosis is anecdotal [25,26], but as seen in the
studies above, this strategy is highly attractive
and will probably be the focus of intense future
research.
CONCLUSION
As discussed in this critical review, the harsh
reality is that clinical evidence for CbAT is
lacking. Most of the studies are relatively small,
and the common theme is the lack of benefit in
primary outcome endpoints, but a positive effect
in secondary endpoints or sub-analyses, such as
faster culture clearance. It is difficult to draw
strong conclusions under these conditions, as
most of these clinical trials were not sufficiently
powered to allow definite conclusions regarding
the primary endpoints chosen. The next genera-
tion of clinical trials should be sufficiently pow-
ered to explore these differences, although, as
previously mentioned, the logistics of such trials
are highly complex. The next generation of
clinical trials will probably explore more combi-
nations with immune modulator agents.
Until more information is available, physi-
cians and pharmacists should approach CbAT
with caution, as a clear area of concern related
to this strategy is the potential ‘financial antago-
nism’ without the benefit of clinically relevant
synergy.
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